
Ampio Pharmaceuticals AMPE
Ampio Pharmaceuticals Gesamtes Eigenkapital | AMPE
Gesamtes Eigenkapital Jährlich Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 M | 11.8 M | 27.3 M | 17.5 M | 6.44 M | 5.24 M | -34.2 M | 6.63 M | 37 M | 66.1 M | 33.1 M | 23.8 M | 17.8 M | -4.01 M | -268 K | 1.08 K |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 66.1 M | -34.2 M | 13.6 M |
Gesamtes Eigenkapital Vierteljährlich Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 6.56 M | 7.88 M | 11.8 M | 13.8 M | 20.1 M | 22.3 M | 27.3 M | 17.3 M | 20.4 M | 16.8 M | 17.5 M | 10.7 M | 6.34 M | 1.99 M | 6.44 M | 4.14 M | 11.1 M | -468 K | 5.24 M | 2.24 M | -3.77 M | 8.9 M | -34.2 M | 199 K | 3.7 M | 5 M | 6.63 M | 9.77 M | 13.1 M | 17.9 M | 37 M | 44.9 M | 51.3 M | 60.3 M | 66.1 M | 73.3 M | 80.2 M | 87.3 M | 33.1 M | 38 M | 18.2 M | 23 M | 23.8 M | 26.7 M | 13.7 M | 15.2 M | 17.8 M | 13.1 M | 14.3 M | 17.8 M |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 87.3 M | -34.2 M | 19.9 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Lyra Therapeutics
LYRA
|
-10.7 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
57 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
125 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-38.9 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
648 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
190 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
212 M | $ 4.2 | -0.71 % | $ 651 M | ||
|
AbbVie
ABBV
|
-3.27 B | $ 293.87 | 0.19 % | $ 520 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 151.6 | -3.2 % | $ 19.9 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
15.8 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | ||
|
Axon Enterprise
AXON
|
3.24 B | $ 302.6 | -0.19 % | $ 23.6 B | ||
|
Theratechnologies
THTX
|
-25.3 M | - | - | $ 83.9 M | ||
|
Liquidia Corporation
LQDA
|
44.7 M | $ 51.37 | 7.31 % | $ 4.42 B | ||
|
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 45.05 | -9.97 % | $ 4.05 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
245 M | $ 48.48 | -5.96 % | $ 5.56 B | ||
|
Geron Corporation
GERN
|
226 M | $ 0.96 | -3.71 % | $ 640 M | ||
|
Bristol-Myers Squibb Company
BMY
|
18.5 B | $ 62.8 | 1.06 % | $ 128 B | ||
|
Titan Pharmaceuticals
TTNP
|
2.44 M | - | -3.76 % | $ 3.47 M | ||
|
Kazia Therapeutics Limited
KZIA
|
12 M | $ 7.4 | -0.13 % | $ 113 M | ||
|
Celldex Therapeutics
CLDX
|
527 M | $ 30.68 | -1.81 % | $ 2.04 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
6.08 M | $ 4.0 | -6.76 % | $ 48.8 M | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
1.02 B | $ 317.26 | 0.99 % | $ 6.14 B | ||
|
Eli Lilly and Company
LLY
|
26.5 B | $ 1 432.7 | 1.47 % | $ 1.29 T | ||
|
TCR2 Therapeutics
TCRR
|
141 M | - | - | $ 58.1 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
TFF Pharmaceuticals
TFFP
|
9.57 M | - | -60.05 % | $ 125 K | ||
|
Mesoblast Limited
MESO
|
597 M | $ 14.0 | -3.06 % | $ 16.9 B | ||
|
CorMedix
CRMD
|
405 M | $ 5.37 | -2.1 % | $ 387 K | ||
|
Adaptimmune Therapeutics plc
ADAP
|
11.8 M | - | -15.15 % | $ 60.3 M | ||
|
MannKind Corporation
MNKD
|
-51 M | $ 4.22 | 0.84 % | $ 1.29 B | ||
|
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | ||
|
MediciNova
MNOV
|
41.6 M | $ 1.4 | -4.76 % | $ 68.7 M | ||
|
Merck & Co.
MRK
|
52.6 B | $ 147.75 | -0.68 % | $ 370 B | ||
|
Moderna
MRNA
|
8.65 B | $ 250.79 | -6.77 % | $ 97.6 B | ||
|
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | ||
|
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | ||
|
Intellia Therapeutics
NTLA
|
671 M | $ 11.18 | -7.72 % | $ 1.21 B | ||
|
Novartis AG
NVS
|
46.5 B | $ 163.39 | -0.18 % | $ 317 B | ||
|
Omeros Corporation
OMER
|
-121 M | $ 17.3 | -1.48 % | $ 1.1 B | ||
|
Oramed Pharmaceuticals
ORMP
|
200 M | $ 3.97 | -0.75 % | $ 164 M | ||
|
Tyme Technologies
TYME
|
80.1 M | - | 8.07 % | $ 54 M | ||
|
Puma Biotechnology
PBYI
|
130 M | $ 8.13 | -3.22 % | $ 407 M |